Effect of Isodon ternifolius-medicated serum on hepatic stellate cells based on TLR4/NF-κB/NLRP3 signaling pathway.
10.19540/j.cnki.cjcmm.20230306.704
- Author:
Gui-Dong HUANG
1
;
Zhi-Pin ZHOU
2
;
Zhi PANG
3
;
Le QIN
1
;
Rui-Sheng WU
1
;
Yong CHEN
1
;
Xiao-Xue YE
2
Author Information
1. School of Pharmacy,Guangxi University of Chinese Medicine Nanning 530001,China.
2. Liuzhou People's Hospital Affiliated to Guangxi Medical University,Guangxi Key Laboratory of Biotechnology Research for Clinical Diseases,Health Commission of Guangxi Zhuang Autonomous Region,Liuzhou Engineering Technology Research Center of Gastrointestinal Chinese Patent Medicine Liuzhou 545006,China.
3. Guangxi Jinxiu Shengtang Pharmaceutical Co.,Ltd. Laibin 545700,China.
- Publication Type:Journal Article
- Keywords:
Isodon ternifolius;
TLR4/NF-κB/NLRP3;
hepatic stellate cells
- MeSH:
NF-kappa B/metabolism*;
Hepatic Stellate Cells;
Transforming Growth Factor beta1/metabolism*;
NF-KappaB Inhibitor alpha/metabolism*;
Intercellular Adhesion Molecule-1/metabolism*;
Isodon;
NLR Family, Pyrin Domain-Containing 3 Protein/metabolism*;
Toll-Like Receptor 4/metabolism*;
Vascular Cell Adhesion Molecule-1/metabolism*;
Lipopolysaccharides/pharmacology*;
Signal Transduction;
Colchicine/pharmacology*;
Caspases
- From:
China Journal of Chinese Materia Medica
2023;48(14):3913-3921
- CountryChina
- Language:Chinese
-
Abstract:
The present study aimed to investigate the inhibitory effect and mechanism of Isodon terricolous-medicated serum on lipopolysaccharide(LPS)-induced hepatic stellate cell(HSC) activation. LPS-induced HSCs were divided into a blank control group, an LPS model group, a colchicine-medicated serum group, an LPS + blank serum group, an I. terricolous-medicated serum group, a Toll-like receptor 4(TLR4) blocker group, and a TLR4 blocker + I. terricolous-medicated serum group. HSC proliferation was detected by methyl thiazolyl tetrazolium(MTT) assay. Enzyme-linked immunosorbent assay(ELISA) was used to measure type Ⅰ collagen(COL Ⅰ), COL Ⅲ, transforming growth factor-β1(TGF-β1), intercellular adhesion molecule-1(ICAM-1), α-smooth muscle actin(α-SMA), vascular cell adhesion molecule-1(VCAM-1), cysteinyl aspartate-specific proteinase-1(caspase-1), and monocyte chemotactic protein-1(MCP-1). Real-time PCR(RT-PCR) was used to detect mRNA expression of TLR4, IκBα, and NOD-like receptor thermal protein domain associated protein 3(NLRP3), nuclear factor-κB(NF-κB) p65, gasdermin D(GSDMD), and apoptosis-associated speck-like protein containing a CARD(ASC) in HSCs. Western blot(WB) was used to detect the protein levels of TLR4, p-IκBα, NF-κB p65, NLRP3, ASC, and GSDMD in HSCs. The results showed that I. terricolous-medicated serum could inhibit the proliferation activity of HSCs and inhibit the secretion of COL Ⅰ, COL Ⅲ, α-SMA, TGF-β1, caspase-1, MCP-1, VCAM-1, and ICAM-1 in HSCs. Compared with the LPS model group, the I. terricolous-medicated serum group, the colchicine-medicated serum group, and the TLR4 blocker group showed down-regulated expression of p-IκBα, NLRP3, NF-κB p65, GSDMD, and ASC, and up-regulated expression of IκBα. Compared with the TLR4 blocker group, the TLR4 blocker + I. terricolous-medicated serum group showed decreased expression of TLR4, p-IκBα, NLRP3, NF-κB p65, GSDMD, and ASC, and increased expression of IκBα. In conclusion, I. terricolous-medicated serum down-regulates HSC activation by inhibiting the TLR4/NF-κB/NLRP3 signaling pathway.
